Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients
Stopped early · Phase 1/Phase 2
Conditions studied: Diabetes Mellitus, Type 1
In brief
Insulin dependent Type I diabetics require daily insulin therapy to normalize blood glucose but may have difficulty with significant glycemic excursions and hypoglycemic episodes and crises. Islet cell transplantation can provide relief from daily insulin therapy, normalize blood glucose and reduce or eliminate short and long-term diabetes-related complications. "PEG-Encapsulated Islet Allografts" is a new islet transplant product under development that does not require the ongoing use of immunosuppressive drugs after the implant. This study will test the safety and efficacy of PEG-Encapsulated Islet Allografts in the treatment of Type I diabetes and provide functional outcome measurements.
Key facts
- Study ID
- NCT00260234
- Run by
- Novocell
- People needed
- 12
- Starts
- 2005-11-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2014-09-09
Who can join
Age: 20 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or non-pregnant non-lactating female subjects > 20 years of age
- Diagnosed with insulin-dependent type I diabetes for at least 20 years
- BMI less than 28 kg/m2
- Insulin requirement less than or equal to 0.7 U/kg/day
- HbA1c greater than or equal to 7.0 %
- Serum C-peptide concentration less than or equal to 0.5 ng/mL stimulated by an OGTT
- Female subjects with childbearing potential must have a negative serum pregnancy test prior to enrollment and must agree to use an effective contraceptive method during the study
- One year of stable diabetes care established in the PI's database without significant changes in insulin requirement or HbA1c or diabetic complication profile
You may not qualify if…
- Diagnosis of type II diabetes or maturity onset diabetes of youth (MODY)
- Serum C-peptide greater than 0.5 ng/mL stimulated by OGTT
- Sustained hypertension greater than or equal to 100 mmHg diastolic and/or greater than or equal to 160 mmHg systolic
- History of myocardial infarction or current active cardiac disease
- Current active infection
- Significant renal dysfunction as indicated by GFR less than 80 mL/min/1.73 m2 and/or urinary albumin greater than 500 µg/mL
- Significant liver dysfunction as indicated by ALT or AST more than 3X the upper limit of normal
- Prior whole organ or islet cell transplant
- Concurrent immunosuppressive therapy
- Severe gastroparesis, severe peripheral neuropathy, diabetic foot ulcers, or prior amputations due to diabetic complications
- Any other active autoimmune disease other than autoimmune thyroid disease
- HIV, HBV or HCV positive status
- Uncontrolled or untreated proliferative retinopathy
- Known hypersensitivity or other intolerance to cyclosporine or the inactive ingredients in the product
- Behavioral activities that place the subject at risk in the opinion of the investigator
- Any significant concurrent disease, illness, or psychiatric disorder that would, in the opinion of the investigator, compromise subject safety or compliance, or interfere with consent, study participation, follow-up, or the interpretation of study results
- History of any kind of cancer other than skin cancers (except for melanoma which is exclusionary)
Where it is running
- CHRISTUS Santa Rosa Transplant Institute — San Antonio, Texas, United States
- Diabetes & Glandular Disease Research Associates, P.A. — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.